世界の成人悪性神経膠腫治療薬市場2022年-2027年:成長・動向・新型コロナの影響・市場予測

【英語タイトル】Adult Malignant Glioma Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Mordor Intelligenceが出版した調査資料(MOR22MA614)・商品コード:MOR22MA614
・発行会社(調査会社):Mordor Intelligence
・発行日:2022年1月
・ページ数:116
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後2-3営業日)
・調査対象地域:グローバル
・産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,750 ⇒換算¥703,000見積依頼/購入/質問フォーム
Site Licence(同一拠点内で共有可)USD6,500 ⇒換算¥962,000見積依頼/購入/質問フォーム
Corporate License(複数拠点内で共有可)USD8,750 ⇒換算¥1,295,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

Mordor Intelligence社の本調査資料では、世界の成人悪性神経膠腫治療薬市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、疾患別(多形性膠芽腫、退形成性星状細胞腫、退形成性乏突起膠腫、退形成性乏突起星細胞腫、その他)分析、治療法別(化学療法、標的薬剤療法、放射線療法)分析、地域別(北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米)分析、競争状況、市場機会・将来の傾向などの項目を掲載しています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・市場動向
・世界の成人悪性神経膠腫治療薬市場規模:疾患別(多形性膠芽腫、退形成性星状細胞腫、退形成性乏突起膠腫、退形成性乏突起星細胞腫、その他)
・世界の成人悪性神経膠腫治療薬市場規模:治療法別(化学療法、標的薬剤療法、放射線療法)
・世界の成人悪性神経膠腫治療薬市場規模:地域別(北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米)
・競争状況(AbbVie, Inc.、Amgen, Inc.、Arbor Pharmaceuticals、Bio Rad Laboratories、Bristol-Myers Squibb Company、F. Hoffmann-La Roche Ltd、Pfizer, Inc.、Sun Pharmaceuticals Ltd、Merck & Co. Inc.)
・市場機会・将来の傾向

The development of a promising drug to treat malignant glioma has proved difficult to date, with many promising candidates failing to achieve the desired test results in the past few years.

However, technological advancements in the diagnosis of gliomas and analysis of its progression, through various imaging modalities, have improved survival rates, thereby giving an enhanced edge for rapid evaluation of the efficacy of several pipeline drugs.

North America and Europe are projected to dominate the global adult malignant glioma therapeutics market during the forecast period, primarily due to the significant reimbursement coverage. The market in the Asia Pacific is expected to expand at a significant CAGR between 2020-2025.

According to the World Health Organization, globally, an estimated 245,000 cases of brain and nervous system tumors are reported each year. Glioblastoma multiforme is the most common and the most lethal of these tumors. Gliomas are categorized under rare diseases; however, the incidence rate across the globe has witnessed a steady rise in the last decade. Adoption of novel drug discovery technologies, such as high-throughput screening and TCGA, has reduced the overall drug discovery time and the cost of drug development. This is attributed to a rising number of players participating in new product development and launches in various therapy areas, including glioma.

Key Market Trends

The Glioblastoma Multiforme Segment is Expected to Exhibit the Fastest Growth over the Forecast Period

In terms of type, the global adult malignant glioma therapeutics market has been classified into glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma, and others. According to the Case Reports in Oncology, 2018, around 200 cases were reported worldwide for glioblastoma multiforme. Consequently, this segment is likely to be the most attractive segment during the forecast period, followed by anaplastic astrocytoma. Intense research and development focus of manufacturers, the presence of significant patient population driving demand for effective therapeutics to improve the overall survival rate, and rapidly increasing the pipeline of innovative novel drugs are attributed to the high growth of the segment.

North America Holds the Largest Market Share

North America is expected to dominate the global market , owing to technological advancement in the adult malignant glioma therapuetics. However, growth of the market in the near future is likely to depend on the combined prospects in technology and opportunity in the developing countries in Asia, such as China, Japan, India, and South Korea. The market in Asia-Pacific is anticipated to register an above average growth rate during the forecast period, owing to a relatively high patient population demanding affordable care and improvements in healthcare infrastructure to aid in the early diagnosis of malignant gliomas.

Competitive Landscape

The leading vendors of the market are expanding their operations in Asian countries (India, China, Japan, and South Korea)m as these economies hold immense potential for glioma products, given the increasing prevalence of neural disorders in the region. The major players operating in the market include Merck & Co. Inc., F. Hoffmann-La Roche Ltd, and Bio-Rad Laboratories, among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
❖ レポートの目次 ❖

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Incurable Status of the Disease
4.2.2 Global Increase in Aging Population
4.2.3 Increasing Prevalence of Brain Disorders
4.3 Market Restraints
4.3.1 Diminishing Preference for Chemotherapy
4.3.2 Low Approval Rates for Novel Therapeutics for Glioma
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 Type of Disease
5.1.1 Glioblastoma Multiforme
5.1.2 Anaplastic Astrocytoma
5.1.3 Anaplastic Oligodendroglioma
5.1.4 Anaplastic Oligoastrocytoma
5.1.5 Other Types of Disease
5.2 Therapy
5.2.1 Chemotherapy
5.2.1.1 Temozolomide
5.2.1.2 Bevacizumab
5.2.1.3 Carmustine
5.2.1.4 Other Types of Chemotherapy
5.2.2 Targeted Drug Therapy
5.2.2.1 Epidermal Growth Factor Receptor (EGFR) Inhibitors
5.2.2.2 Other Monoclonal Antibodies
5.2.3 Radiation Therapy
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AbbVie, Inc.
6.1.2 Amgen, Inc.
6.1.3 Arbor Pharmaceuticals
6.1.4 Bio Rad Laboratories
6.1.5 Bristol-Myers Squibb Company
6.1.6 F. Hoffmann-La Roche Ltd
6.1.7 Pfizer, Inc.
6.1.8 Sun Pharmaceuticals Ltd
6.1.9 Merck & Co. Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS



★調査レポート[世界の成人悪性神経膠腫治療薬市場2022年-2027年:成長・動向・新型コロナの影響・市場予測] (コード:MOR22MA614)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の成人悪性神経膠腫治療薬市場2022年-2027年:成長・動向・新型コロナの影響・市場予測]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆